<SEC-DOCUMENT>0001387131-13-004709.txt : 20131218
<SEC-HEADER>0001387131-13-004709.hdr.sgml : 20131218
<ACCEPTANCE-DATETIME>20131218080017
ACCESSION NUMBER:		0001387131-13-004709
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20131213
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131218
DATE AS OF CHANGE:		20131218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		131283952

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>txmd-8k_121313.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"><FONT STYLE="text-transform: none">Washington,
D.C. 20549</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center">FORM
8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-transform: uppercase; text-align: center">SECURITIES
EXCHANGE ACT OF 1934<BR>
</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Date of Report (Date of earliest event
reported): December 13, 2013</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 0pt; text-align: center; font-size: 18pt"><FONT STYLE="font-size: 18pt"><B>THERAPEUTICSMD, INC.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 30pt; text-align: center">(Exact Name of Registrant as Specified
in its Charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>000-16731</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>87-0233535</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or Other</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Jurisdiction of Incorporation)</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer</FONT><BR>
<FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">6800 Broken Sound Parkway NW,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Third Floor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Boca Raton, FL 33487</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Office) (Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 24pt 0; text-align: center">Registrant's telephone number, including
area code: (561) 961-1900</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(<I>see</I> General Instruction A.2 below):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt; text-align: right"><FONT STYLE="font-family: Wingdings 2">&pound;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="width: 0pt; text-align: right"><FONT STYLE="font-family: Wingdings 2">&pound;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt">
<TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="text-align: right; width: 0pt"><FONT STYLE="font-family: Wingdings 2">&pound;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt">
<TR STYLE="vertical-align: top; text-align: justify"><TD STYLE="text-align: right; width: 0pt"><FONT STYLE="font-family: Wingdings 2">&pound;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 10%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: -1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
    5.02.</B></FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 80%">Departure
    of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
    Officers.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: -1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: -1in"><B><I>Resignation
of Samuel A. Greco</I></B>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">On December 13, 2013, Samuel A. Greco
resigned from the board of directors (the &ldquo;Board&rdquo;) of our company. On behalf of the Board, Tommy Thompson, Chairman
of the Board, thanked Mr. Greco for his contribution to our company and wished him well in his future endeavors. Pursuant to the terms of 2009 Long Term Incentive Compensation
Plan (the &ldquo;Plan&rdquo;), Mr. Greco has three months to exercise his vested stock options following his resignation from the
Board. In connection with Mr. Greco&rsquo;s resignation, the Board accelerated the vesting of Mr. Greco&rsquo;s unvested stock
options to the date of his resignation from the Board and extended the period during which Mr. Greco may exercise his vested stock
options to six months following the period set forth in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Appointment of Randall S. Stanicky</I></B>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On December 13, 2013, the Board appointed Randall
S. Stanicky to serve as a director to fill the vacancy created by Mr. Greco&rsquo;s resignation. At this time, Mr. Stanicky has
not been named to serve on any committee of the Board. There is no arrangement or understanding between Mr. Stanicky and any other
person pursuant to which he was selected as a director, and there are no related party transactions with respect to Mr.&nbsp;Stanicky
reportable under Item 404(a) of Regulation&nbsp;S-K. Mr. Stanicky has not entered into any material plan, contract, or arrangement and
has not received any grant or award under any material plan, contract, or arrangement in connection with his appointment to the
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We issued a press release announcing the resignation
of Mr. Greco and the appointment of Mr. Stanicky on December 18, 2013, a copy of which is attached as Exhibit 99.1 hereto and incorporated
herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
    9.01.</B></FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 80%">Financial Statements and Exhibits.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center">(d)</TD>
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif">Exhibits.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">Exhibit</TD></TR>
</TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       <TR STYLE="vertical-align: top">
<TD><U></U></TD><TD STYLE="text-decoration: underline"><U>Number</U></TD><TD><U>&#9;Description</U></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 11%"></TD><TD STYLE="width: 8%">99.1</TD><TD STYLE="width: 81%">Press Release dated December 18, 2013</TD></TR></TABLE>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt; text-align: justify">Date: December 18, 2013</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">THERAPEUTICSMD, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 0pt; text-align: justify; font-style: italic"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    <I>Daniel A. Cartwright</I></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt; text-align: justify">Daniel A. Cartwright</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt; text-align: justify">Chief Financial Officer</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 243pt; text-align: center; text-indent: -243pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>EXHIBIT INDEX</B></P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: right; text-indent: -1.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt">
<TR STYLE="vertical-align: top">
    <TD>Exhibit</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: underline">Number</TD>
    <TD STYLE="text-decoration: underline">Description</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">99.1</TD>
    <TD NOWRAP STYLE="width: 34%"><A HREF="ex-99_1.htm">Press Release dated December 18, 2013</A>&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: left; text-indent: -1.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: left; text-indent: -1.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: left; text-indent: -1.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99_1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><A HREF="txmd-8k_121313.htm">TherapeuticsMD, Inc. 8-K</A></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>EXHIBIT 99.</B>1</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>FOR IMMEDIATE RELEASE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD NAMES RANDALL S. STANICKY
TO BOARD OF DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Boca Raton, FL - December 18, 2013 &ndash;
</B>TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women&rsquo;s healthcare company (&quot;TherapeuticsMD&quot; or the &quot;Company&quot;),
announced today that Randall S. Stanicky, CFA, a highly-regarded senior equity analyst with extensive experience in the specialty
pharmaceutical and healthcare services sectors, has been named to its Board of Directors, replacing Samuel A. Greco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Stanicky currently serves as Managing Director,
Global Equity Research at RBC Capital Markets, focusing on the specialty pharmaceuticals sector and has spent almost 15 years in
equity research covering healthcare stocks. He previously served in senior roles at Goldman Sachs and Canaccord Genuity on the
sell side. His prior coverage experience within the healthcare sector has been broad, spanning specialty pharmaceuticals, the healthcare
supply chain, contract research and healthcare technology. Prior to that, he followed healthcare stocks on the buy side at Citigroup
Global Asset Management. &nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;We are pleased to welcome Randall Stanicky
to our Board of Directors,&rdquo; said the Honorable Tommy G. Thompson, Chairman of TherapeuticsMD. &ldquo;His extensive knowledge
of the specialty pharmaceuticals sector along with his analytical and financial acumen will offer a welcome and broadened perspective
to the Company as we advance the development of our portfolio of hormone therapy products. We thank Samuel Greco for his valuable
contributions to the Board of Directors and extend our appreciation for his service.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;Mr. Stanicky is a well-respected senior
research analyst and we are delighted to have him join our Board,&rdquo; said Robert Finizio, Chief Executive Officer and Co-founder
of TherapeuticsMD. &ldquo;The insight and knowledge gained from his successful career as an equity analyst covering specialty pharmaceuticals
will be important as we build the Company&rsquo;s leadership position in women&rsquo;s healthcare. We are grateful to have someone
of his caliber on our team and we look forward to his contributions,&rdquo; added Mr. Finizio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About TherapeuticsMD, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">TherapeuticsMD,
Inc. is a women&rsquo;s healthcare company focused on developing and commercializing products targeted exclusively for women. We
are developing advanced hormone therapy pharmaceutical products based on novel technologies that enable delivery of bioidentical
hormones through a variety of dosage forms and administration routes. We also manufacture and distribute branded and generic prescription
prenatal vitamins, as well as over-the-counter vitamins and cosmetics, under our vitaMedMD<SUP>&reg;</SUP> and BocaGreenMD<SUP>&reg;</SUP>
brands. More information is available at the following websites: </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">www.therapeuticsmd.com</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">www.vitamedmd.com</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">www.vitamedmdrx.com</FONT>,
and <FONT STYLE="font-family: Times New Roman, Times, Serif">www.bocagreenmd.com</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">.<FONT STYLE="color: #0070C0">
</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Except for the historical information contained
herein, the matters set forth in this press release, including statements regarding the Company&rsquo;s belief in Mr. Stanicky&rsquo;s
attributes and how those attributes will affect the Company are forward-looking
statements within the meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including
but not limited to: timely and successful completion of clinical studies and the results thereof; challenges and costs inherent
in product marketing; the risks and uncertainties associated with economic and market conditions; risks and uncertainties associated
with the Company&rsquo;s business and finances in general; and other risks detailed in the Company&rsquo;s filings with the U.S.
Securities and Exchange</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Commission including its annual report on Form 10-K filed on March 12, 2013, reports on Form 10-Q and Form
8-K, and other such filings. These forward-looking statements are based on current information that may change. Investors are cautioned
not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking
statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or
update any forward-looking statement to reflect events or circumstances after the issuance of this press release.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Contacts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TherapeuticsMD, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dan Cartwright, 561-961-1930</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: blue">Dan.Cartwright@TherapeuticsMD.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In-Site Communications (Investor Relations)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Lisa M. Wilson, 917-543-9932</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: blue">lwilson@insitecony.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Red Fox Communications (Public Relations)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Judy Grossman, 917-913-1690</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: blue">judy@redfoxcomm.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: right">&nbsp;</P>



<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``R`=X#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#J?&/Q8O\`
MPSXJO=(@TNWGCM]F)'=@3N16[?[U8?\`PO75?^@):_\`?;5[>T,3L6:)&)[E
M0::UO!M/[F/I_<%;JI32LX_B<\J55MM3_`\1_P"%[:F?^8+:?]_&I?\`A>NJ
M_P#0%M?^^VKF_A@JM\3K%64$;IN",_P-7TC]F@_YXQ_]\BM:OLZ;MRF%'VM6
M/-SV^1Q/P[\>W?C274%N;&&V%LJ%3&Q.[=N]?I7&Q>/O$S?%7^Q3J>=/_M0V
M_D^1'_J_,QC=MST[YS7M:1QQYV(JYZ[1BOF^)E3XWLS,%5=:8DDX`'FFII*,
MG)VZ%UG."BF^I])45YQK?QF\/Z9<M;V44^HNIP7BPL?X,>OX#%4K'XYZ/-.J
M7NF7=JA./,1A(!]1P?RS62H5&KV-GB*2=KGJE%5=.U*SU>QCO;"X2XMI!E9$
M/!_P/M5JLC9.^P45P?B#XM>'-#G>VB>74+A#AEML%%/H6/'Y9K!A^.^G-(!/
MHETD?=DE5C^1`_G6JHU&KI&+Q%).S9ZU16'X<\7:-XJMVDTN[#N@S)"XVR)]
M1Z>XXK5O;I+&PN+MU9D@B:5@O4A1GC\JS<6G9FJDFKK8GHKBO"OQ+TOQ9J,U
MG;6MU;F&$S/)/M"A00#R"?6L[6OC-X=TRX:"S2?474X+PX6/\&/7\!BK]E.]
MK&?MJ=N:^AZ-16'IOBBRO/"4/B*Z_P!#M'C\Q_,.[8-V.H'-<AJ'QM\.6SE+
M2WO;S'\2H$4_]]'/Z4E3G)V2'*K"*NV>ET5Y1#\=M):0"?1[R-/[R.K'\N*[
MOP[XNT;Q3`TFEW8D=!F2%QMD3ZCT]QQ3E2G'5H4*U.;M%FY161XF\06_A?0Y
MM5NHI988BH*18W'<0.Y'K6+HGQ)T/5]$O-6E,EA:VL@C9KG&6)&0%`)R?;K4
MJ$FKI%.I%/E;U.QHKRJ]^.>D13LEGI5W<H#C>[B//T'-7M&^,_AW49EAO8KC
M3W8X#R`/'^)'(_*K="HE>Q"Q%)NUST>BF12QSPI+#(LD;C<KH<AAZ@T\D`$D
MX`K(V"BN!U_XN^'-%G:V@:749U.&^S8V`_[QX/X9K#@^.VFM*!/HMU''GEDE
M5C^1`_G6JHU&KI&+Q%).S9ZU16+X=\5Z/XIMC-I=V)"G^LB8;73ZK_7I4OB/
M78/#6AW&JW,4DL4&W<D>-QR0.,_6HY7?EZFG-&W-?0U:*YGP=XULO&<%U+96
MUQ`+9E5A-MYR#TP3Z5TU*47%V8XR4E=!17-^,/&5EX-L[:YO;>XG6>0QJ(<9
M!`SSDBIM&\56FM^%7\00031VZI(YC?&_"9ST..U/DE;FZ$\\>;EOJ4?%_C_3
MO!EQ:PWUM=3-<(SJ80IP`<<Y(]:WM'U.+6M'M-2@1TBN8Q(JOC<`?7%?/'Q(
M\:V/C.\L)K*VN(!;1LC";;R20>,$^E==X;^,.C:+X;T_3)M/OWEMH%C9D";2
M1Z9:NB6'?(FEJ<T<2O:--Z=#V>O)/'_Q'\0>&O%4NFZ=#:M;K$C`R0LQR1D\
M@BNY\(>,+/QEI\]Y96\\*0R^4RS8R3@'L3ZUE>*_B9I?A/61IMY8W<TIB63=
M$%VX.?4CTK.G%J=G&YK5DG"ZE9=SJ](NI+[1;&[F`$L]O'(X48&YE!./SJY4
M=O,MQ;13*"%D0.`>H!&:Q/$?C+0_"T8.IW@65AE((QND;\.P]S@5FDY.R1JY
M**NV;]%>23?'?3A(1!HET\?9GF53^0!_G6SHGQB\-ZK,L%UYVG2,<`S@%,_[
MPZ?B!5NA42O8S6(I-V3/0J*1'61%=&#*PR&!R"/6N1\4?$C0/"LYM;B22YO0
M.;>W`)7_`'B2`/IU]JB,7)V1I*<8J\F=?17DR?';3#)B31;M4]5D4G\N/YUU
M_A[XB^&_$DR6]I>&*Z?A;>X78S'T'8_@:J5&<5=HB->G)V3.CO9S:V%Q<*H8
MQ1,X![X!-<)H'Q,74=6CL]0MHK:.7Y4E5C@-VSGL:[75_P#D"W__`%[R?^@F
MO#]$\.3:]8:E+:DFYM`KI'_ST!SD?7CBM:$(2BW(\[,,17IUH*CYZ=['OM%<
M)\/_`!:=2MQI%^Y^VP+B-F/,BCM]1_+\:[NL9P<)69Z&'KPKTU4@%>>^(/B8
MNG:M)9Z?;17*1?*\K,<%NX&.PJSX_P#%ATVW.DV#DWTXP[+UC4_U/\OPKSO7
M?#DV@66FO=$BZNU:1X_^>8!&!]>>:Z*%&+LY]=CR\QQU2-X4/L[O]#W:RG-U
M86UPRA6EB5R!VR`:\\N_B3J46L7-A;Z3'.T4KQJ%+%F"DC.!]*[W1_\`D"6'
M_7M'_P"@BO+?#/\`R5>;_KXN/Y/44HQ?,VKV-L;5JKV482MS.QK?\+"\0#EO
M#;@?[D@_I4]G\5+;S1'J6FS6YS@M&V['U!Q7H54=2T;3M7A,5]:13`C`++\P
M^AZBESTWO$T>'Q4=85;^J0[3=5L=7MA<6%RDT??:>5/H1U%-O]7LM-9$N9MK
ML,A0"3CUXKRO6M+U#X>ZY#?Z;.S6<IPI;OZH_K_GTKO8[6R\6V%MJT,FP31@
M.C#<,KN'/(Y4LU$J48VE?W6*CBZE3FIN-JBZ=/5'06]Q#=P)/!()(G&0PJ6J
MUC9I8VHA1F?YF=G;JS$Y)X]S5FL7OH>A&]E?<*1ONGZ4M(WW3]*0SYL^%_\`
MR5"P_P!Z;_T!J^E*^:_A?_R5"P_WIO\`T!J^E*Z<5\:]#CP7\-^H5\L>(+&;
M4_B5J5A;_P"NN=3DB3/JTA%?4]?-T'_)<?\`N-M_Z--/#.W,_(,8K\J\SV?0
M/AYX<T&RCB73H+J<+^\N+B,.SGN>>@]A67XY^'6BZKH5W<V5C!::A!&TL<D"
M!`Y`SM8#@YQUKOJJ:I_R";W_`*X/_P"@FL54ES7N=$J4.7EL>*?`[6)XM=O=
M'+DV\\)F5<\*ZD#(^H/Z"NE^,OBNXTG2[?1K*0QS7P+3.IP1$.,#ZG]`?6N(
M^"W_`"/I_P"O23^:U?\`CI;2IXFTZZ(/E26FQ3[JQ)_]"%=<HIXA7.&,Y+#.
MQT/PR^&VG+HUOK>LVJ75S<J)(891E(T/0D'J3UYZ<5Z'>^&=#U"V:WNM)LY(
MB,8\E01]".1^%>.Z'\+]7UK0[/4;/Q0H@GB#*HW_`">J]>QR/PK0_P"%-^(/
M^AI'_D3_`!K.:3E=S-:;E&"2I_D<KXFTN[^&/CN&XTN9Q"<3VY8]4)PR-Z]Q
M],5[M?7T6I^![J_A_P!5<Z<\J_1HR:\MF^"&L7)!G\0PRD="Z.V/S->D)I4F
MA_#B73)91,]MITD9=1@-A#2JRC)1L[L=&,XN5U9,^:M#@U._U$:5I;N)K_$#
M*IQN7.2"?[O&3]*]YT#X0>'-+M4_M"$ZC=X^=Y&(0'_94'I]<UYY\$X$E\<2
MRL,M%:.R>Q)49_(G\Z^A*K$U)*7*B,)2BX\TM3/.B:?_`&&^C);)'8/$T/DI
MP`ISG'YURD?ACX=^%U$=U'IB2KU-]*KN?P8_R%9?Q@\87VA6=KI>FRM!/>*S
MRS)PRH.,*>Q)SS[>]<[X.^$4>NZ3!K&MZA.HNE\U(8<;BIZ%F.>O7I40C:'-
M*5DS6<TY\D(W:.UN8OAEK$36[R:#\PP&C=(F'T88->0$-X$^)2#3KL3003H4
MD5P1)"V"5)'!X./J*]1E^"/AETQ'<ZE&WKYJG_V6O(O%/A^#PQXT;2K>Y:XC
MB:,[W`!Y`.#CZUM1<6VDVSGQ"FDI.*7FCV[XN\_#B_\`]^+_`-#6O(/AWX,E
M\9:C)%<321:5:D23[3]YCT4=@3CKZ"O7OBW_`,DVOO\`?A_]#6N9^!%];_8=
M6T\L!<^8LP'=DQC]"/UJ*<G&@VNYI5BIXA*78]%L/!_AS3;<06VBV00#!+PA
MV/U+9)KDO''PMTG5-+GN]'M([/48E+JL(VI-CG:5Z`GL1WKTBHKFXBM+:6YG
M<)%$A=V/0`#)-<T:DD[IG5*E"4;-'B?P7\57$.J/X;NI&:WE5I+<,?\`5N.2
M![$9/U'O6W\9_%=QIMC;Z%92&.2\4R7#J<'R\X"_B<Y^GO7!?#2)[_XHVD\"
MD1H\LS?[*[6_Q`_&M3XX6LL?B^TN6!\J:T4(>V59LC]1^==CA'VZ.&,Y?5WZ
MV.L^&OPVTVWT:VUC6+5+J\N5$L<4R[DB0\K\IX)(YYZ5WM_X7T+4K5K:[TFS
M>,C'$04CZ$<C\*\@T?X6:QJ^C6>H6GBE?(N(E=`-_P`O'3KVZ?A5[_A3?B#_
M`*&D?^1/\:RFDY7<S6FY1BDJ?Y'*:]87GPO\?QRZ=*YA&)H"Q^_$3@HWKT(_
M(UZQ\2;N._\`A7=WD)S%/'#(GT+*1_.N,F^"&L7+!I_$,,I`P"Z.<?F:ZGQM
MIDFD?!F337D$SVL$,3.HP#M91FJE*,I0L[LF$9QC.ZLK&+\!_P#D&ZS_`-=8
MOY-7KU>/_`:1/L6M1;AO$D3;?;#5[!6.(_B,Z,+_``D>3_';_D`Z5_U\M_Z#
M6Y\)HDF^&MI%*@>-VF5E89!!<Y!K`^.\T8TC2(2P\QIW<+WP%P3^HKHOA#_R
M3JQ_ZZ2_^AFK?\!>IG'_`'E^G^1YU\9M&TS1]1TI--L+>T62%RX@C";B",9Q
M7H7@OPCX=O?!>D7-SHEA-/);(SR/`I9CZDXKB_CQ_P`A31O^N$G_`*$*].\!
M?\B%HG_7HG\JJ<G[&+N33BO;R5C5TW2-.T>%X=-LH+2-VW,D*!03Z\5X)\:?
M^1]7_KSC_FU?1%?._P`:?^1]7_KSC_FU3A7>H5C%:EH>P:_XA7POX"_M/:&E
M2WC2%3T:1@`/P[_05X_X!\(S?$'6[S5M;N)9+6-\S-N^::0\[<]ACKCM@#V[
MKXJVLL_POLY(P2L#P/)C^[M*Y_,BH?@;J%O)X<OM/!47$-SYK+W*LH`/YJ15
M0]VDY1W)FN>M&$MK'>VOA7P_96X@M]&L%C'8P*2?J2,G\:Y+Q5\(M%UM/.TM
M4TN[R,F-?W;#/.5['Z8KT2BN>-247=,Z94H25FC*T31(?#GA^'3+%I)%@0A6
ME;)9OZ<]AP*^<_"MSI2^.O.\7J7A,C^;YJD@2D]7'IG-?4-<9XH^&6@>*)WN
MY$DM+U_O3VY`WGU93P?KP?>M*551OS=3*M1<E'DZ=#6@TSPKK5E_HUEI-W;$
M?\LHHV&/P'%4=)^'?AW1/$!UBQM&CF"%4C+;DC)ZLH/(...M>;WOP8U_2W:X
MT/5XYG7E0"T$GX$$C]13O!GQ&U[2_$D7A[Q*9)E>86Y:8?O87)P,G^(9QU]<
MYJ_9MI^SE<CVB4DJD+'LFK_\@6__`.O>3_T$UYY\)?\`CYU7_=C_`)M7H>K_
M`/(%O_\`KWD_]!->>?"7_CYU7_=C_FU33_@R^1AB?]]H_/\`(D\>>&)M.NQX
MDTC=&R.'G$?5&_OCV]?_`-=7A\2;3_A%/MAV_P!J?ZK[/_MX^]_N]_TKO'19
M$9'4,K#!4C((]*\['PRC'BOSB1_8_P#K=F?FSG[GT]_3WIPG"4;5.G]6(KX>
MO1J.>%VENNS[D?@/PS-?W9\2ZONDDD8O`LG5C_?/]/S]*K_%K_C\TK_<D_FM
M>HJJHBHBA548``P`*\N^+7_'YI7^Y)_-:JE4<ZR;(QF'CA\#*$?*[[NZ/1='
M_P"0)8?]>T?_`*"*\M\,_P#)5YO^OBX_D]>I:/\`\@2P_P"O:/\`]!%>9^'+
M2Y3XHRS/;RK$;BX^<H0.C=ZFEM/T+QB;E0]5^AZS1117,>L<S\0+>.X\&7I<
M<Q;'4^AW`?R)K(^%,SOX?NXF.5CN/E]LJ*@^)WB&)+%=$MW#SR,&GVG[BCD`
M^Y.#^'O6_P"!-&DT;PS"DZ[;B=C-(IZC/0?D!73\-"SZL\I-5,PO#[*LSI:*
M**YCU0I&^Z?I2T4`?-OPPC=?B=8$HP&Z;DC_`&&KZ2IH10<A0#]*=6M6I[1W
ML8T:7LH\M[A7SA!&_P#PN_=L;']MMSC_`*:FOH^F[%SG:,^N**=3DOIN%6E[
M2VNPZJFJ?\@F]_ZX/_Z":MT5D;,^>?@O&Z^/"65@/LDG4>ZU['XT\)6WC#0F
ML97\JX0[[>;&=C^_L>A_^M71!%4Y"@'V%+6M2JY3YUH84Z"A#D>I\]:;K'C#
MX57$EG=V)ET]GW;)`3$Q_O(XZ$__`*Q712?'A/(_=>'V\['\5S\H/_?->Q.B
MR(5=0RGJ",@U472=-1]Z:?:*_P#>$*@_RJW5A+64=2%0J1TA/0\:TB^^(GCC
MQ%;:E;ROIMI`V5?85@53U&T_ZPD?7\*]?UT,/#.IACN;['*"0.IV'M6E16<Z
MG,U96L:TZ7*G=W;/`?@BCKXQNRRL!]C;J/\`:6O?J0*J]%`^@I:*M3VDN8*-
M+V<>6YYQ\5_!%WXFLK:_TQ?,O;,,IASS(AYX]P>W?-<7X7^*FI>$K&/1=9TJ
M29+8;(\DQRHO]T@CG'X5[W4,]G;70`N+>&;'3S$#?SJHU5R\LE=$3H/GYX.S
M/)+CXR:CJQ^Q^&_#TKW;\*SDR%??:H_F:\SUO3=8L?%6S6MSZA(Z33'.XY;!
MY(XSSVKZH@MH+9=L$$<2^D:!1^E2%%)R5!/TJXUXP?NQ(GAI37O2.&^+?_)-
MK[_?A_\`0UKQOPCH7B*6SF\1^&Y&-U83!&BC^^5(SD#HP[$?SKV7XN_\DYO_
M`/KI%_Z&*Y_X$?\`(#U;_KY7_P!!JZ<G&BWYD58*==1?8SK;XX7]FA@U;P^&
MND&&*2F+GW4@XK$UKQOXK^(@_LG3-.>.UD(WPVP+%O\`??T_(5[]/8VET0;B
MU@F(Z&2,-_.I(H8H$V0Q)&G]U%`'Z5FJL%JHZFCHU):2GH<3\./`*^#[&2XN
MV235+E0)"O*QKUV`]_<_X5I^-_!]OXQT0VCN(KJ(E[:8C[K>A]CW_`]JZ:BL
MG4DY<_4V5**AR6T/GK2]=\7_``LG>POM/:6P+$B.3)C)]8W'3/\`D5T,WQX3
MR/W'A]O./3?<_*#^"U[$Z)(A1U5E/4,,@U532=.C?>FGVJO_`'EA4'^5:NK"
M6LHZF*HU(Z0GH>.Z'=_$3QKXDM]5CFDTVRA/#E"L`4]0%/\`K"?\D5[!J^EP
MZUHMWIET3Y5S$8V8#D9[CZ'FKU%9SJ<S32M8UITN5--WN?-*P>*/A7XC:X6`
M[.4\PJ6@N$^O^2*ZW_A>UP\`2/P^IN3P#]H)7/TVY_6O9W19$*.H93U##(-0
M1:=8P2>9#9V\;_WDB4'\P*U=:,M9QNS)8><-(2LCYM\90>*=5@A\2>((FB6X
M?R;>`J5*J!GA>P^O)KV+X1@K\.[$$$'S)>O^^:[@J&Z@'ZT``#```]JF=;GA
MRV*IX?DGSWN>7_&7PK?:UI]GJ>GPO/)9[UEB098H<'<!WP1^M<?X9^+U]X<T
M6'2;K2DNA;#9&_F&-@.P(P<X_"OH&J\EC:2R>9):P._]YHP3^=$:RY>22N$Z
M#Y^>$K,YSP%XGOO%FCW&H7MDMH!.4B10V"FT'.3UY)Y%>2?&B-V\>*55B/LD
M?0>[5]#``#`&`*0HK')4$^XI0JJ$^9(=2BYT^1LSHK*WU'PY%97<0D@GM5CD
M0]P5%>':OX,\4?#O7/[6T$S7%HI.R:)=Q"_W9%]/?I]*^@Z*5.JX>C'4HJ:7
M1H\6M/CO.D&V^T%7G'!:*<H"?H5./SK)U'QGXR^(CC3='L9+>U8C>MMGG_?D
M.,#\OQKW272]/GD\R:QMI'_O/"I/YD59CCCA0)&BH@Z*HP!5^U@M8QU,W1J2
MTE/0Y[3+#Q'I_@O[++?P7FMK$1'-,#L#=@3U;'J>M>5P^,?B!X'G>#6[*6\M
M]Q.ZY4L.O\,B_P#U_I7N](0&!!`(/4&HC42O=7N:3I-VY9-6/''^/"&W.SP^
MWGXXS<_+G_OG-8_A'PUK?C7QNOB;5;9H+03K</(R%0Y7&U4!ZC@#/H/6O<AI
MM@LGF"RM@_\`>$2Y_/%6JKVT8I\D;$>PE)IU)7L4]7_Y`M__`->\G_H)KSSX
M3*RW.JY!'RQ]?JU>GT@4#H`/I41J6@X]Q5,-SUX5K_#?\1:***S.H*\N^+*L
MUYI952<))T^JUZC2%0>H!K2G/DES'/B\/]8I.G>USS*S^*`M;&WMSHTC>5&J
M;O/QG`QG[M3_`/"UQ_T!)/\`P(_^QKT;8O\`='Y4;%_NC\JOVE/^7\3G6&Q2
M5E6_\E1YP?BOD870WW=LS_\`V-5Y?%7C'Q`/(TK2WM4;@R*AR/\`@;<"O3PJ
MCHH_*EH]I!;1!X3$2TG6=O))?B<'X8^'JV-TNHZS*+J\#;UCSN56]23]X_YY
MKO***SG.4W>1U4,/3H1Y::"BBBH-@HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
)**`"BBB@#__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
